Published in Cost Eff Resour Alloc on July 17, 2009
Estimating the burden of disease in chronic pain with and without neuropathic characteristics: does the choice between the EQ-5D and SF-6D matter? Pain (2014) 1.49
Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain. Health Qual Life Outcomes (2013) 1.24
Pharmacist-led management of chronic pain in primary care: costs and benefits in a pilot randomised controlled trial. BMJ Open (2015) 0.92
The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure. Eur J Health Econ (2010) 0.91
Can Original Knee Society Scores Be Used to Estimate New 2011 Knee Society Scores? Clin Orthop Relat Res (2017) 0.84
An 8-Week Knee Osteoarthritis Treatment Program of Hyaluronic Acid Injection, Deliberate Physical Rehabilitation, and Patient Education is Cost Effective at 2 Years Follow-up: The OsteoArthritis Centers of America(SM) Experience. Clin Med Insights Arthritis Musculoskelet Disord (2014) 0.81
Using QALYs in telehealth evaluations: a systematic review of methodology and transparency. BMC Health Serv Res (2014) 0.80
Can The EQ-5D Detect Meaningful Change? A Systematic Review. Pharmacoeconomics (2015) 0.78
The impact of preoperative patient characteristics on health states after total hip replacement and related satisfaction thresholds: a cohort study. Health Qual Life Outcomes (2014) 0.77
Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD). Eur J Health Econ (2014) 0.77
Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis. Int J Inflam (2013) 0.76
Long-term clinical benefit and cost-effectiveness of an 8-week multimodal knee osteoarthritis management program incorporating intra-articular sodium hyaluronate (Hyalgan(®)) injections. J Pain Res (2017) 0.75
A single-blinded, randomized, parallel group superiority trial investigating the effects of footwear and custom foot orthoses versus footwear alone in individuals with patellofemoral joint osteoarthritis: a phase II pilot trial protocol. J Foot Ankle Res (2017) 0.75
The impact of preoperative patient characteristics on the cost-effectiveness of total hip replacement: a cohort study. BMC Health Serv Res (2014) 0.75
Should additional domains be added to the EQ-5D health-related quality of life instrument for community-based studies? An analytical descriptive study. Popul Health Metr (2015) 0.75
Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients. Eur J Health Econ (2012) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol (1988) 35.68
EuroQol: the current state of play. Health Policy (1996) 27.78
Modeling valuations for EuroQol health states. Med Care (1997) 21.66
The estimation of a preference-based measure of health from the SF-36. J Health Econ (2002) 14.18
Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess (1998) 9.32
Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care (2002) 6.63
A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ (2004) 4.42
Longitudinal construct validity: establishment of clinical meaning in patient evaluative instruments. Med Care (2000) 3.44
Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol (1997) 3.37
A brief screening tool for knee pain in primary care (KNEST). 2. Results from a survey in the general population aged 50 and over. Rheumatology (Oxford) (2003) 3.22
Generic and condition-specific outcome measures for people with osteoarthritis of the knee. Rheumatology (Oxford) (1999) 2.51
A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage (2002) 2.14
Patient-reported outcome in total hip replacement. A comparison of five instruments of health status. J Bone Joint Surg Br (2004) 2.08
The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D. Int J Obes (Lond) (2006) 1.93
A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthritis Cartilage (2002) 1.89
Relationship among sociodemographic factors, clinical conditions, and health-related quality of life: examining the EQ-5D in the U.S. general population. Qual Life Res (2005) 1.86
An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ (2003) 1.74
Responsiveness of generic health-related quality of life measures in stroke. Qual Life Res (2005) 1.62
Reliability and validity of the EuroQol in patients with osteoarthritis of the knee. Rheumatology (Oxford) (1999) 1.58
Variation in the estimation of quality-adjusted life-years by different preference-based instruments. Med Care (2003) 1.52
Comparison of the responsiveness and relative effect size of the western Ontario and McMaster Universities Osteoarthritis Index and the short-form Medical Outcomes Study Survey in a randomized, clinical trial of osteoarthritis patients. Arthritis Care Res (1999) 1.48
Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. Health Technol Assess (1998) 1.32
A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care (2004) 1.27
Economic evaluation and decision making in the UK. Pharmacoeconomics (2006) 1.21
Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum (2007) 1.19
Inconsistent responses in three preference-elicitation methods for health states. Soc Sci Med (1999) 1.18
An assessment of the discriminative ability of the EQ-5Dindex, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions. Eur J Health Econ (2007) 1.18
Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets. J Health Econ (2005) 1.16
The Arthritis, Diet and Activity Promotion Trial (ADAPT): design, rationale, and baseline results. Control Clin Trials (2003) 1.13
A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ (2009) 1.10
Economic evaluation of a rehabilitation program integrating exercise, self-management, and active coping strategies for chronic knee pain. Arthritis Rheum (2007) 1.09
Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res (2005) 1.08
Supplementation of a home-based exercise programme with a class-based programme for people with osteoarthritis of the knees: a randomised controlled trial and health economic analysis. Health Technol Assess (2004) 1.08
Measuring health-related utility: why the disparity between EQ-5D and SF-6D? Eur J Health Econ (2005) 1.05
Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. Ann Rheum Dis (2004) 1.03
Responsiveness of the electronic touch screen WOMAC 3.1 OA Index in a short term clinical trial with rofecoxib. Osteoarthritis Cartilage (2004) 0.98
Prioritization of patients on waiting lists for hip and knee replacement: validation of a priority criteria tool. Int J Technol Assess Health Care (2004) 0.97
Assessing the needs and quality of life of patients with HIV infection: development of the HIV Overview of Problems-Evaluation System (HOPES). Qual Life Res (1992) 0.93
The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol (2003) 0.88
Cost-utility and cost-effectiveness analyses of a long-term, high-intensity exercise program compared with conventional physical therapy in patients with rheumatoid arthritis. Arthritis Rheum (2005) 0.88
EQ-5D versus SF-6D in an older, chronically Ill patient group. Appl Health Econ Health Policy (2004) 0.88
Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ-5D. Br J Psychiatry (2009) 0.85
Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol (2009) 0.84
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Medication-related clinical decision support in computerized provider order entry systems: a review. J Am Med Inform Assoc (2006) 6.39
What evidence supports the use of computerized alerts and prompts to improve clinicians' prescribing behavior? J Am Med Inform Assoc (2009) 4.07
Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology (2007) 4.06
Extended prescribing by UK nurses and pharmacists. BMJ (2005) 3.99
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62
Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet (2012) 3.48
British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) (2007) 3.39
Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. BMJ (2011) 3.29
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13
Contingent valuation: what needs to be done? Health Econ Policy Law (2010) 2.83
Prescribing safety features of general practice computer systems: evaluation using simulated test cases. BMJ (2004) 2.67
Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. Arthritis Rheum (2009) 2.47
Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ (2004) 2.39
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis (2013) 2.33
Mobile phone use and risk of glioma in adults: case-control study. BMJ (2006) 2.20
A review of human factors principles for the design and implementation of medication safety alerts in clinical information systems. J Am Med Inform Assoc (2010) 2.10
A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22. Arthritis Rheum (2010) 2.02
Epidemiology of gout. Arthritis Res Ther (2010) 1.99
Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol (2007) 1.99
Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf (2005) 1.97
Sex and ethnic differences in the association of ASPN, CALM1, COL2A1, COMP, and FRZB with genetic susceptibility to osteoarthritis of the knee. Arthritis Rheum (2007) 1.95
A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5' UTR of GDF5 with osteoarthritis susceptibility. Hum Mol Genet (2008) 1.91
A randomised controlled trial of ion-exchange water softeners for the treatment of eczema in children. PLoS Med (2011) 1.90
Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis (2007) 1.86
Age and sex differences in hip joint space among asymptomatic subjects without structural change: implications for epidemiologic studies. Arthritis Rheum (2003) 1.81
Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol (2014) 1.80
Evaluation and certification of computerized provider order entry systems. J Am Med Inform Assoc (2006) 1.80
A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol (2013) 1.77
Meta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteoarthritis on chromosome 7q22. Ann Rheum Dis (2010) 1.75
The GDF5 rs143383 polymorphism is associated with osteoarthritis of the knee with genome-wide statistical significance. Ann Rheum Dis (2010) 1.70
The causes of prescribing errors in English general practices: a qualitative study. Br J Gen Pract (2013) 1.66
The changing epidemiology of gout. Nat Clin Pract Rheumatol (2007) 1.66
Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet (2002) 1.63
Evaluation of the genetic overlap between osteoarthritis with body mass index and height using genome-wide association scan data. Ann Rheum Dis (2012) 1.62
Equity in health care financing: The case of Malaysia. Int J Equity Health (2008) 1.61
Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis. BMJ (2012) 1.61
A variant in MCF2L is associated with osteoarthritis. Am J Hum Genet (2011) 1.60
Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ (2013) 1.58
Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis (2012) 1.50
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
Prevalence and associations of hallux valgus in a primary care population. Arthritis Rheum (2008) 1.46
Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis. Am J Hum Genet (2008) 1.45
Reproducible genetic associations between candidate genes and clinical knee osteoarthritis in men and women. Arthritis Rheum (2006) 1.44
Sexual activity and prostate cancer risk in men diagnosed at a younger age. BJU Int (2008) 1.43
Lack of support for the presence of an osteoarthritis susceptibility locus on chromosome 6p. Arthritis Rheum (2005) 1.40
Involvement of different risk factors in clinically severe large joint osteoarthritis according to the presence of hand interphalangeal nodes. Arthritis Rheum (2010) 1.33
Genetic variation in the SMAD3 gene is associated with hip and knee osteoarthritis. Arthritis Rheum (2010) 1.29
Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis. Proc Natl Acad Sci U S A (2012) 1.28
11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat (2012) 1.26
An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford) (2009) 1.24
Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology (2014) 1.24
Are joints affected by gout also affected by osteoarthritis? Ann Rheum Dis (2007) 1.23
History of allergies and risk of glioma in adults. Int J Cancer (2006) 1.21
Polypharmacy: one of the greatest prescribing challenges in general practice. Br J Gen Pract (2011) 1.19
Prescribing errors and other problems reported by community pharmacists. Ther Clin Risk Manag (2005) 1.19
An assessment of the discriminative ability of the EQ-5Dindex, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions. Eur J Health Econ (2007) 1.18
Interaction between 5 genetic variants and allergy in glioma risk. Am J Epidemiol (2010) 1.16
Comparing cost-utility estimates: does the choice of EQ-5D or SF-6D matter? Med Care (2009) 1.15
Pathophysiology of articular chondrocalcinosis--role of ANKH. Nat Rev Rheumatol (2010) 1.14
Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS One (2012) 1.13
A comparison of the performance of the EQ-5D and SF-6D for individuals aged >or= 45 years. Health Econ (2008) 1.13
Inverse relationship between preoperative radiographic severity and postoperative pain in patients with osteoarthritis who have undergone total joint arthroplasty. Semin Arthritis Rheum (2011) 1.12
Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet (2004) 1.11
How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme. Drug Saf (2013) 1.10
Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health Qual Life Outcomes (2008) 1.09
Planned implementations of ePrescribing systems in NHS hospitals in England: a questionnaire study. JRSM Short Rep (2010) 1.09
Nottingham knee osteoarthritis risk prediction models. Ann Rheum Dis (2011) 1.08
Hypersomnia following traumatic brain injury. J Clin Sleep Med (2007) 1.08
Morphologic differences between the hips of Chinese women and white women: could they account for the ethnic difference in the prevalence of hip osteoarthritis? Arthritis Rheum (2011) 1.06
The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis. Ann Rheum Dis (2011) 1.05